Evidence map›Paper›PMID 38768058›Full record

ReviewBiomolecules & biomedicine2024

Metabolic dysregulation in obese women and the carcinogenesis of gynecological tumors: A review.

Dragana Tomić Naglić, Aljoša Mandić, Andrijana Milankov, Slađana Pejaković, Stefan Janičić, Nikolina Vuković, Ivana Bajkin, Tijana Ičin, Mia Manojlović, Edita Stokić

Abstract readReview
In one paragraph

Review in Biomolecules & biomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dragana Tomić NaglićUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Diabetes and Metabolic Disorders, Clinic for Endocrinology, Clinical Center of Vojvodina, Novi Sad, Serbia.
Aljoša MandićUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Institute of Oncology of Vojvodina, Sremska Kamenica, Serbia.
Andrijana MilankovUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Diabetes and Metabolic Disorders, Clinic for Endocrinology, Clinical Center of Vojvodina, Novi Sad, Serbia.
Slađana PejakovićUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Diabetes and Metabolic Disorders, Clinic for Endocrinology, Clinical Center of Vojvodina, Novi Sad, Serbia.
Stefan JaničićUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Diabetes and Metabolic Disorders, Clinic for Endocrinology, Clinical Center of Vojvodina, Novi Sad, Serbia.
Nikolina VukovićUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Diabetes and Metabolic Disorders, Clinic for Endocrinology, Clinical Center of Vojvodina, Novi Sad, Serbia.
Ivana BajkinUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Diabetes and Metabolic Disorders, Clinic for Endocrinology, Clinical Center of Vojvodina, Novi Sad, Serbia.
Tijana IčinUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Diabetes and Metabolic Disorders, Clinic for Endocrinology, Clinical Center of Vojvodina, Novi Sad, Serbia.
Mia ManojlovićUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Diabetes and Metabolic Disorders, Clinic for Endocrinology, Clinical Center of Vojvodina, Novi Sad, Serbia.
Edita StokićUniversity of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Diabetes and Metabolic Disorders, Clinic for Endocrinology, Clinical Center of Vojvodina, Novi Sad, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a significant health issue associated with increased cancer risks, including gynecological malignancies. The worldwide rise in obesity rates is significantly impacting both cancer development and treatment outcomes. Adipose tissue plays a crucial role in metabolism, secreting various substances that can influence cancer formation. In obese individuals, dysfunctional adipose tissue can contribute to cancer development through inflammation, insulin resistance, hormonal changes, and abnormal cholesterol metabolism. Studies have shown a strong correlation between obesity and gynecological cancers, particularly endometrial and breast cancers. Obesity not only increases the risk of developing these cancers but is also associated with poorer outcomes. Additionally, obesity affects the perioperative management of gynecological cancers, requiring specialized care due to increased complications and resistance to therapy. Treatment strategies for managing metabolic dysregulation in patients with gynecological cancers include weight management, statin therapy, and insulin-sensitizing medications. Emerging studies suggest that interventions like intermittent fasting and caloric restriction may enhance the effectiveness of cancer treatments. Furthermore, targeting cholesterol metabolism, such as with statins or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, shows potential in cancer therapy. In conclusion, addressing metabolic issues, particularly obesity, is crucial in preventing and treating gynecological malignancies. Personalized approaches focusing on weight management and metabolic reprogramming may improve outcomes in these patients.

Indexed as

Genital Neoplasms, FemaleObesityAdipose TissueCarcinogenesisFemaleHumansInsulin Resistance

Identifiers

PMID38768058
PMCPMC11293241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.